4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. It also develops 4D-175 for geographic atrophy in preclinical with open IND; 4D-725 for alpha-1 anti-trypsin deficiency lung disease in preclinical; and 4D-310 for Fabry disease, which is in Phase 1 clinical trials. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; uniQure biopharma B.V; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Period	Net Profit Margin
2020-12-31	-416.49%
2021-12-31	-395.37%
2022-12-31	-3435.41%
2023-12-31	-486.59%
2024-12-31	-434778.38%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FDMT	$10.12	-1.17%	0.49M
3
4
5

4D Molecular Therapeutics Inc. (FDMT) Profit Margin

Profit Margin Data

Get 4D Molecular Therapeutics Inc. Data in Excel

More FDMT Financial Data